PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that at least five antibodies generated from
Medarex's UltiMAb(R) technology in which Medarex wholly owns or has an
economic interest through co-promote/profit sharing rights, royalties
and/or equity ownership, are expected to be the subject of oral or poster
presentations at the 71st Annual Meeting of the American College of
Rheumatology (ACR), being held November 6-11, 2007 in Boston.
Golimumab (CNTO 148) and ustekinumab (CNTO 1275) Phase III or Phase II
clinical data for inflammatory diseases in development by Medarex's
licensing partner, Centocor, Inc.
-- "Golimumab, a new, human TNF-alpha antibody administered as a monthly
subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy
and safety results of the randomized, placebo-controlled GO-RAISE
study" (Presentation #L10, Spondylarthropathies and Psoriatic Arthritis
Session) - Poster presentation scheduled for Thursday, November 8, 2007
at 8:00 A.M.
-- "Characterization of golimumab (CNTO 148), a novel monoclonal antibody
specific for human TNFa" (Presentation #274, RA Treatment: Small
Molecules Sessions) - Poster presentation scheduled for Thursday,
November 8, 2007 at 8:00 A.M.
-- "Phase II, randomized, placebo-controlled study of CNTO 1275, a human
interleukin-12/23 monoclonal antibody, in psoriatic arthritis"
(Presentation #L16, Spondylarthropathies and Psoriatic Arthritis
Session) - Oral presentation scheduled for Saturday, November 10, 2007
at 3:15 P.M.
-- "Golimumab, a new human TNF-alpha antibody administered as a monthly
subcutaneous injection in psoriatic arthritis: 24-week efficacy and
safety results of the randomized, placebo-controlled GO-REVEAL study"
(Presentation #L14, Spondylarthropathies and Psoriatic Arthritis
Session) - Oral presentation scheduled for Saturday, November 10, 2007
at 2:45 P.M.
On November 1, 2007, Johnson & Johnson announced that it will sponsor
an analyst meeting and webcast on Thursday, November 8, 2007, from
5:00-6:00 P.M. Eastern Time to discuss late-stage compounds, including
golimumab and ustekinumab.
Ofatumumab (HuMax-CD20) Phase II clinical data for rheumatoid arthritis
in development by Medarex's licensing partner, Genmab A/S
-- "Ofatumumab, a human CD20 monoclonal antibody, in the treatment of
rheumatoid arthritis: early results from an ongoing, double-blind,
randomized, placebo controlled clinical trial" (Presentation #2086, RA
Treatment: Small Molecules Session) - Poster presentation scheduled for
Saturday, November 10, 2007 at 3:00 P.M.
MEDI-545 Phase I clinical data for systemic lupus erythematosus in
development by Medarex's partner, MedImmune, Inc.
-- "Safety of MEDI-545, an anti-interferon-. monoclonal antibody, in
MI-CP126, a phase I study in systemic lupus erythematosus (SLE)"
(Presentation #428, SLE Session) - Poster presentation scheduled for
Thursday, November 8, 2007 at 8:00 A.M.
-- "Neutralization of type I IFN inducible genes in phase I trial of
anti-IFNa mAb for the treatment of SLE: utility as pharmacodynamic
markers" (Presentation #429, SLE Session) - Poster presentation
scheduled for Thursday, November 8, 2007 at 8:00 A.M.
-- "Anti-IFN-a antibody neutralization of early and late transcriptional
responses in PBMC stimulated with serum from SLE patients"
(Presentation #840, Genetics, Genomics and Proteomics Session) - Poster
presentation scheduled for Friday, November 9, 2007 at 8:00 A.M.
-- "MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence
of clinical activity in systemic lupus erythematosus" (Presentation
#1315, SLE Session) - Oral presentation scheduled for Friday, November
9, 2007 at 2:30 P.M.
Preclinical data for an anti-CD70 antibody in development by Medarex
-- "Functional blocking and targeted depletion of activated lymphocytes by
fucosylated and non-fucosylated fully human anti-CD70 IgG1"
(Presentation #1984, T-cell Biology and Targets in Autoimmune Disease
Session) - Poster presentation scheduled for Saturday, November 10,
2007 at 8:00 A.M.
Abstracts and information about the ACR and its Annual Meeting may be
found at http://www.rheumatology.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase III clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Media, Jean Mantuano, Corporate
Communications, Inc., x2221, or Investor Relations, Laura S.
Choi, x2216, both of Medarex, Inc., +1-609-430-2880
|
